Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00075231 | A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects | PHASE2 | COMPLETED | 150 | — | — | Dec 1, 2003 | - | Oct 2, 2006 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Kaletra® (lopinavir/ritonavir) | DRUG | - |
| Combivir® (lamivudine, zidovudine) | DRUG | - |
| Sustiva® (efavirenz) | DRUG | - |
Inclusion Criteria * Subject is at least 18 years of age. * Subject is confirmed HIV positive and in the investigator's opinion requires antiretroviral (ARV) therapy. * Subject is naïve to HIV ARV therapy or has received \< 7 days total of any HIV ARV therapy \> 30 days prior to study drug administ...